Litcius/Paper detail

Transforming properties of <scp>MET</scp> receptor exon 14 skipping can be recapitulated by loss of the <scp>CBL</scp> ubiquitin ligase binding site

Marie Fernandes, Sonia Paget, Zoulika Kherrouche, Marie‐José Truong, Audrey Vinchent, Jean‐Pascal Meneboo, Shéhérazade Sebda, Elisabeth Werkmeister, Clotilde Descarpentries, Martin Figeac, Alexis B. Cortot, David Tulasne

2023FEBS Letters19 citationsDOIOpen Access PDF

Abstract

MET is a receptor tyrosine kinase that is activated in many cancers through various mechanisms. MET exon 14 (Ex14) skipping occurs in 3% of nonsmall cell lung tumors. However, the contribution of the regulatory sites lost upon this skipping, which include a phosphorylated serine (S985) and a binding site for the E3 ubiquitin ligase CBL (Y1003), remains elusive. Sequencing of 2808 lung tumors revealed 71 mutations leading to MET exon 14 skipping and three mutations affecting Y1003 or S985. In addition, MET exon 14 skipping and MET Y1003F induced similar transcriptional programs, increased the activation of downstream signaling pathways, and increased cell mobility. Therefore, the MET Y1003F mutation is able to fully recapitulate responses induced by MET exon 14 skipping, suggesting that loss of the CBL binding site is the main contributor of cell transformation induced by MET Ex14 mutations.

Topics & Concepts

Ubiquitin ligaseExonExon skippingMutationDNA ligaseMolecular biologyCancer researchCell biologyBiologyUbiquitinChemistryGeneticsGeneAlternative splicingLiver physiology and pathologyPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations
Transforming properties of <scp>MET</scp> receptor exon 14 skipping can be recapitulated by loss of the <scp>CBL</scp> ubiquitin ligase binding site | Litcius